Drug Profile
Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland
Alternative Names: Cobicistat/darunavir/emtricitabine/GS 7340; Cobicistat/darunavir/emtricitabine/GS 7340 fixed-dose combination - Janssen; Darunavir/cobicistat/emtricitabine/GS-7340; Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide; Darunavir/emtricitabine/GS 7340/cobicistat; Emtricitabine/GS 7340/cobicistat/darunavir; GS 7340/cobicistat/darunavir/emtricitabine; SYMTUZA; Tenofovir alafenamide/cobicistat/darunavir/emtricitabineLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences; Tibotec Pharmaceuticals
- Developer Gilead Sciences; Janssen R&D Ireland
- Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides
- Mechanism of Action Cytochrome P 450 enzyme system inhibitors; DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase II inhibitors; DNA-directed DNA polymerase inhibitors; HIV protease inhibitors; HIV reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in Netherlands (PO, Tablet)
- 28 Nov 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In children) in Spain (PO, Tablet)
- 28 Nov 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In children) in USA (PO, Tablet)